Lung Cancer

Papers
(The H4-Index of Lung Cancer is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England135
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients112
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy107
175 External Validation of a Left Anterior Descending Coronary Artery Dose Constraint in Patients with Non-Small Cell Lung Cancer: An NI–HEART Analysis100
190 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status76
251 Optimising engagement and addressing inequalities for patients using a Digital Behaviour Change Intervention in lung cancer prehabilitation: A mixed-methods study75
260 Second Primary Lung Cancer Cohort Study (SPORT)73
101 Treating advanced EGFR positive non-small cell lung cancer patients with Osimertinib - the University Hospital Plymouth experience69
107 Osimertinib Efficacy in Advanced NSCLC Patients with PACC and Classical-Like EGFR Mutations: A Retrospective Analysis from The Christie63
98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer60
74 The first-in-class PRX3 inhibitor RSO-021 modulates the composition of malignant pleural effusions by eliciting immunomodulation and decreasing epithelial to mesenchymal protein expression59
89 Why do almost half of our patients not complete 12 months of maintenance durvalumab after successful radical chemoradiotherapy?56
86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer56
Title Page55
Contents50
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma48
The first historical description of malignant mesotheliomas47
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study45
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study45
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes43
Spatial microenvironment heterogeneity in therapy-naïve lung cancer: A concept with more attention needed42
Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent40
Author index40
The role of mediastinoscopy following EBUS40
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting39
Indwelling pleural catheter infections: a cautionary tale39
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion38
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry38
APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma38
Neighborhood matters: Predicting lung cancer screening adherence with explainable AI37
Corrigendum to “Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)” [Lung Cancer 210 (2025) 108840]35
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial34
Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch134
38 Prehabilitation for Patients Undergoing Radical Radiotherapy for Lung Cancer33
125 Concurrent chemoradiotherapy for inoperable NSCLC in an aging population - is it safe over seventy?33
0.4317741394043